research

In a recent study published in the Journal of Neuroimaging, a team of researchers from the UCLA have reported the first evidence that obstructive sleep apnea contributes to a breakdown of the blood–brain barrier, which plays an important role in protecting brain tissue. The findings are significant for…

In a new study entitled “Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses,” researchers investigated how breastfeeding impacts risk for disease relapse in women with multiple sclerosis. The study was published in the journal JAMA Neurology. Around 20 to 30% of women with…

In a new study entitled “Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity,” researchers identified variations in genes coding for microRNAs that influence patients’ susceptibility to develop multiple sclerosis, as well as the disease course. Most importantly, these variations were gender specific, identified only…

Cryoport, Inc., a leader in providing advanced cryogenic logistics solutions for the life sciences industry, has just announced it will be supplying Opexa Therapeutics’ lead personalized T-cell immunotherapy research initiatives for Multiple Sclerosis (MS) and Neuromyelitis Optica (“NMO”). Opexa’s breakthrough immunotherapy drug platform has shown the potential to improve the lives of…

Multiple sclerosis (MS) is a disease characterized by the destruction of insulating covers on nerve cells by the immune system. The most common form for the disease, relapsing-remitting MS, is characterized by clearly defined attacks of decreasing neurologic function (relapses) followed by partial or complete recovery…

A new study published in the American Journal of Occupational Therapy assessed the cognitive factors affected in multiple sclerosis patients concerning their activity and participation in everyday life. The study is entitled “Factors That Moderate Activity Limitation and Participation Restriction in People With Multiple…

Omnicare, a Fortune 500 company based in Cincinnati, Ohio that provides comprehensive pharmaceutical services to patients and providers across the United States, recently made a generous donation of $100,000 to the National Multiple Sclerosis Society’s inaugural No Opportunity Wasted (NOW) campaign. The NOW campaign aims to raise $250 million to help boost ongoing research…

A recently published study in the journal Neurology entitled “lower physical activity is associated with higher disease burden in pediatric multiple sclerosis” suggests pediatric patients with multiple sclerosis can benefit from engaging in regular moderate to strenuous activity, in that physical activity was linked to a…

In a new review entitled “Fatigue in multiple sclerosis: a look at the role of poor sleep” author Lauren Strober, PhD explores the link between secondary fatigue and sleep disturbance in multiple sclerosis patients. The study was published in the journal Frontiers in Neurology.

Clinical stage biotech company Vitae Pharmaceuticals, Inc., recently announced the launch of a Phase I multiple ascending dose clinical study of VTP-43742, the company’s first-in-class RORγt inhibitor pipeline drug, indicated for the treatment of autoimmune diseases such as multiple sclerosis (MS) and several other orphan indications. Preclinical studies of VTP-43742 exhibited the…

Apitope, a biocompany devoted to drug discovery and development for autoimmune diseases, announced that its partner Merck Serono has concluded the recruitment of participants for its Phase IIa Trial on relapsing multiple sclerosis, (known as a Phase IIa study of ATX-MS-1467 or also M2736) The drug, ATX-MS-1467, is an…

A recent research study focused on whether regular exercise can benefit children with multiple sclerosis (MS). The article appeared in the August 12, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. MS is characterized by inflammation, which manifests as an…

The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation (MSSRF) have announced the awarding of a $3.2 million grant in support of the Canadian Pediatric Demyelinating Disease Network. Canada has the highest rate of multiple sclerosis (MS) in the world, and is one of the…

A new study published in the journal Statistical Methods in Medical Research revealed a new method to determine the disease course in multiple sclerosis (MS) patients. The study is entitled “Joint assessment of dependent discrete disease state processes” and was conducted by researchers at…

Most people know that eating too much salt is bad for your health, but a new study suggests that it could also increase the risk for multiple sclerosis (MS). The work appeared in the August 2015 issue of The FASEB Journal, the journal of the Federation of…

A new study testing Amarantus Diagnostics’ MSPrecise on multiple sclerosis patients identified the test as a specific and sensitive diagnostic test for multiple sclerosis. The test accurately diagnosed 84% of multiple sclerosis patients from a broad range of subjects with potential neurological diseases. These results further support Amarantus Diagnostics’ ability to design next generation…

In a new study entitled “Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data” researchers investigated how polymorphonuclear cells — important players of the innate immune system — are altered in multiple sclerosis patients. The study was published in the journal PLOS…

The major challenge patients with multiple sclerosis face is nearly constant muscle weakness and fatigue caused by progressive nerve and neurological damage. It is well established that these symptoms dramatically affect quality of life in MS patients, making it more difficult to work, partake in hobbies, and enjoy family and social interactions.

Personalized medicine, often applied to treat cancer, may be possible for patients with multiple sclerosis as well. Certain patients respond differently to certain multiple sclerosis medications, such as interferon-β (IFNβ), and researchers at San Raffaele Scientific Institute in Milan may have an answer as to why. The team, led by…

Multiple sclerosis (MS) is a devastating, progressive disease of the nervous system. It is caused by loss of myelin, a fatty substance that wraps around nerve cells and allows them to conduct impulses and communicate. When myelin is lost, areas of damage called “lesions” result, which appear in the brain and…

Fingolimod, also known by its brand name Gilenya, is an oral immunotherapy approved for the treatment of relapsing-remitting multiple sclerosis (MS). In a recent study published in the Journal PLOS One, a team of researchers found that the autonomic cardiovascular dysfunction in MS patients with delayed heart ratere-acceleration…

A study recently published in the journal PLoS One revealed an excess mortality rate among French patients with multiple sclerosis (MS) that experience the disease for more than 20 years. The study was conducted by researchers at several institutes and hospitals in France, and is entitled “…

Summit, New Jersey based Celgene Corporation and Receptos, Inc. of San Diego, California, a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, have announced their joint signing of a definitive agreement in which Celgene will acquire Receptos. Under terms of the merger agreement,…

Skin problems may be caused by interferon-β, a common treatment for multiple sclerosis (MS), according to a new study published by a German research group at the Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, in Würzburg, Germany. The work, entitled “Cutaneous Adverse Events Associated with Interferon-β…

The Multiple Sclerosis Trust — a UK charity dedicated to providing information for anyone affected by multiple sclerosis, education programs for health professionals, funding for practical research and campaigning for specialist multiple sclerosis services, says the recent Update on UK report shows little improvement in meeting key objectives for…

In a recent study published in the International Journal of Molecular Sciences, a team of researchers from Germany identified an association between increased physical activity and improved mental health in patients with Multiple Sclerosis (MS). Based on the results, the researchers believe that physical activity and exercise have considerable health…

Nano-drugs encased in liposomes could one day be used to treat neurological diseases like multiple sclerosis (MS), according to a new study published July 6th in the journal, PloS One. A liposome is a small, fat soluble droplet that can contain a water soluble drug. Liposomes might…

Researchers at Spedali Civili of Brescia in Italy recently published findings in the journal PLoS One that Biogen’s Tysabri (natalizumab) can improve cognitive impairment in patients with relapsing remitting multiple sclerosis (RRMS) over the course of at least three years. The study is entitled “Natalizumab Significantly…

The ability to assess risk may decline as multiple sclerosis disease status progresses over time, as determined by a recent study from University of Alberta in Canada. Principal investigator Esther Fujiwara, PhD, and lead author of the study, Ashley Radomski, used the game of dice task (GDT) to challenge patients…

A new study led by researchers at the Center for BrainHealth at the University of Texas at Dallas and The University of Texas Southwestern Medical Center recently revealed that multiple sclerosis (MS) patients experience cognitive deficits due to a decreased connectivity between functional networks in the brain. The…